Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt.

The Moderna Laboratory has begun the so-called phase 1 trial stage of an HIV vaccine using messenger RNA technology in the United States, on 56 uninfected adults, both the biotech company and the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Its early-stage programs look ambitious, too; for instance, it's developing a potential HIV vaccine. Moderna's mRNA platform has proven successful. If it can continue lining up positive data ...

“Our portfolio already included four of those: SARS-CoV-2, HIV, Nipah and Zika.” Now, Moderna will deploy its mRNA technology to research vaccine approaches for the remaining 11 ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Africa bears a disproportionate infectious disease burden, with HIV, tuberculosis, and malaria posing ongoing threats ...

A view of the headquarters of vaccine maker Moderna on May 08, 2020 in Cambridge, Massachusetts. - Image: Maddie Meyer / Staff (Getty Images) Moderna and other vaccine maker stocks plummeted ...